{"Title": ["Is Acadia Pharmaceuticals a Buy?", "BUZZ-U.S. STOCKS ON THE MOVE-ARCA Biopharma, Aerpio Pharma, Triumph Group", "BUZZ-U.S. STOCKS ON THE MOVE-Blue Hat, ARCA Biopharma, Aerpio Pharma", "BUZZ-U.S. STOCKS ON THE MOVE-Xenetic Biosciences, Dycom, Dynavax Technologies", "BUZZ-U.S. STOCKS ON THE MOVE-Dynavax Technologies, Arbutus Biopharama, Flotek", "BUZZ-U.S. STOCKS ON THE MOVE-Centric Brands, Fulgent Genetics, Moderna", "BUZZ-U.S. STOCKS ON THE MOVE-Centric Brands, Fulgent Genetics, Moderna", "Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer", "Is Acadia Pharmaceuticals a Buy?", "Clovis Oncology's Rubraca gets U.S. FDA approval for prostate cancer", "5 Top Stock Trades for Thursday: AAPL, SPY, WFC, CLVS, SAVE", "Noteworthy Tuesday Option Activity: CLVS, SPG, AAP", "Why Clovis Oncology Stock Marched Higher in April", "From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now", "Clovis Oncology (CLVS) Q1 2020 Earnings Call Transcript", "U.S. FDA gives broader approval to GSK's Zejula for ovarian cancer", "Clovis Oncology's Rubraca gets U.S. FDA approval for prostate cancer", "Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology", "Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today", "Notable Tuesday Option Activity: MCD, HD, CLVS", "Why Clovis Oncology Stock Is Tanking Today", "Here's Why Clovis Oncology Has Upside Potential in 2020", "What's Behind Clovis Oncology's Mixed Q4 Results", "Clovis Oncology (CLVS) Q4 2019 Earnings Call Transcript", "Biotech Stocks Facing FDA Decision In May 2020", "Here's Why Clovis Oncology Lost as Much as 11.8% Today", "4 Stocks Looking Higher", "Why Clovis Oncology Stock Is Popping Today", "2 Incredibly Cheap Cancer Stocks to Buy Now", "Notable Wednesday Option Activity: CLVS, OKTA, TTD", "Here's Why Clovis Oncology Rose as Much as 25.6% Today", "FDA Gives Clovis Oncology's Rubraca a Priority Review", "Clovis Oncology's Sales Growth Slows in Q4", "Here's Why Clovis Oncology Stock Sank 41.9% in 2019", "FDA Nod For MRK, All Eyes On AGTC, ACTION Boosts APLT", "Clovis Oncology Reports Preliminary Fourth Quarter Sales of Rubraca and Sells Additional Shares", "3 Top Biotech Stocks to Buy in January", "Why Clovis Oncology Stock Is Sinking Today", "Are These Biotech Companies Buyout Candidates? Deal Or No Deal?", "This Pharma Stock Soared More Than 360% in November", "All the 2020 Pre-JPM News Healthcare Investors Need to Know", "Here's Why Clovis Oncology Stock Sank 41.9% in 2019", "Is Clovis Oncology Really a Buyout Candidate?", "3 Top Growth Stocks to Buy in December", "Noteworthy Wednesday Option Activity: DXCM, EXPE, CLVS", "The Return of M&A Activity Is Lifting These Biotech Stocks Today", "These 3 Value Stocks Are Absurdly Cheap Right Now", "Today's Top 5 Gainers In Healthcare Sector (IDYA, ELMD, CLBS\u2026)", "Thursday's ETF Movers: CQQQ, IBB", "Top 6 Gainers In Healthcare Sector Today (CRVS, CLVS, TGTX\u2026)", "Today's Top 5 Gainers In Healthcare Sector (HEPA, ENDP, CLVS...)", "3 Beaten-Up Biotechs -- Are They Buys?", "Health Care Sector Update for 10/11/2019: CLVS,GERN,ACRS,HEXO,HEXO.TO", "Will The Pace of M&A Pick Up Following The Biotech Sector\u2019s Pounding?", "3 Cancer Treatment Stocks to Buy Right Now", "Here's Why Clovis Oncology Fell as Much as 13.5% Today", "Clovis Oncology (CLVS) Q3 2019 Earnings Call Transcript", "Top 6 Gainers In Healthcare Sector Today (CRVS, CLVS, TGTX\u2026)", "Notable Thursday Option Activity: VRA, CLVS, TSCO", "Clovis Oncology (CLVS) Q2 2019 Earnings Call Transcript", "Here's Why Clovis Oncology Stock Fell as Much as 15.6% Today", "Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment", "Here's Why Clovis Oncology Stock Dropped as Much as 13% Today", "Notable Monday Option Activity: HRI, ESPR, CLVS", "Near an All-Time Low, Is Clovis Oncology a Buy?", "Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment", "Here's Why Clovis Oncology Stock Dropped as Much as 13% Today", "Notable Monday Option Activity: HRI, ESPR, CLVS", "Clovis Oncology halts mid-stage bladder cancer trial, shares drop", "Clovis Oncology Enters Oversold Territory (CLVS)", "CLVS Crosses Above Key Moving Average Level", "Clovis Oncology Inc (CLVS) Q4 2018 Earnings Conference Call Transcript", "Health Care Sector Update for 04/15/2019: ASMB, APHA, CLVS, JNJ, PFE, MRK, ABT, AMGN", "AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study", "Here's Why Clovis Oncology Stock Jumped on Wednesday", "The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis", "Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More", "Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?", "Consumer Sector Update for 02/19/2019: MOR,CNDT,ICPT,CLVS,ALKS", "Health Care Sector Update for 02/19/2019: CNDT,ICPT,CLVS,ALKS", "Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover", "AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study", "Here's Why Clovis Oncology Stock Jumped on Wednesday", "The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis", "3 Biotech Stocks That Soared This Week: Are They Buys?", "Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options", "Here's Why Clovis Oncology Rose as Much as 21.9% Today", "Immunomedics Enters Into Supply Deal for Breast Cancer Drug", "Notable Friday Option Activity: CARA, CLVS, TCX", "AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting", "3 Biotechs Gilead Sciences Could Buy in March", "Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?", "Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher", "Could These Be the Next 2 Biotech Buyouts?", "Health Care Sector Update for 12/04/2018: CLVS, CRON, MO, PSTI, JNJ, PFE, MRK, ABT, AMGN", "Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%", "Noteworthy Friday Option Activity: CLVS, ABBV, AAL", "Health Care Sector Update for 12/04/2018: GERN,CLVS,PSTI", "Why GlaxoSmithKline, Clovis Oncology, and Tesaro Are on the Move Today", "Clovis (CLVS) Up 45.1% Since Last Earnings Report: Can It Continue?", "Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up", "TESARO Shares Rally on Rumors of Potential Acquisition Offer", "Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA", "AstraZeneca's Lynparza Gets Priority Review in 1st Line Use", "TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer", "TESARO (TSRO) Q3 Earnings Beat, Revenues Miss, Shares Up", "Here's Why Clovis Oncology Got Crushed Today", "Clovis (CLVS) Q3 Earnings & Sales Lag, Rubraca Disappoints", "Health Care Sector Update for 10/31/2018: CLVS, EXAS, SNY, JNJ, PFE, ABT, MRK, AMGN", "Health Care Sector Update for 10/31/2018: ICPT,NUVA,EXAS,CLVS", "Health Care Sector Update for 10/31/2018: NUVA,EXAS,CLVS", "Clovis Oncology (CLVS) Reports Q3 Loss, Misses Revenue Estimates", "Here's Why Clovis Oncology Stock Dropped a Whopping 60.4% in October", "TESARO (TSRO) Q3 Earnings Beat, Revenues Miss, Shares Up", "Here's Why Clovis Oncology Dropped as Much as 21.2% Today", "Health Care Sector Update for 10/19/2018: AVXL, VLRX, CLVS, JNJ, PFE, ABT, MRK, AMGN", "Here's Why Clovis Oncology Inc. Is Losing Ground Today", "Health Care Sector Update for 10/19/2018: MACK, AVXL, CLVS, JNJ, PFE, ABT, MRK, AMGN", "Clovis' Rubraca Gets Breakthrough Therapy Status for mCRPC", "Company News For Oct 3, 2018", "Here's Why Tesaro Inc. Dropped 13.8% Today", "Mid-Afternoon Market Update: Stitch Fix Falls After Q4 Results; Pyxus International Shares Climb", "Why Is Clovis (CLVS) Down 12.9% Since Last Earnings Report?", "Notable Wednesday Option Activity: CLVS, UTX, AXDX", "Interesting CLVS Put And Call Options For November 16th", "Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Beat", "TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2", "IYH's Holdings Imply 11% Gain Potential", "Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options", "Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options", "Health Care Sector Update for 07/05/2018: CLVS,APOP,AZRX,ZYNE", "AstraZeneca/Merck's Lynparza Betters Survival in Phase III", "Interesting CLVS Put And Call Options For August 17th", "Notable Tuesday Option Activity: MGM, CLVS, GBT", "Clovis Oncology (CLVS) Up 11.5% Since Earnings Report: Can It Continue?", "Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today", "Clovis Gets EU Acceptance for Rubraca Label Expansion Filing", "Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat", "What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?", "Health Care Sector Update for 04/17/2018: JNJ, ARQL, AVXL, NVCR, CLVS", "Health Care Sector Update for 04/17/2018: ARQL,NCVR,JNJ,CLVS", "Health Care Sector Update for 04/17/2018: NVCR,JNJ,CLVS", "Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy", "Clovis Oncology (CLVS) Surges: Stock Moves 5.9% Higher", "Clovis' Rubraca Gets Approval in Europe for Ovarian Cancer", "Clovis (CLVS) Q1 Loss Wider Than Expected, Revenues Beat", "Tesaro Wants a Stronger Grip in Ovarian Cancer", "Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug", "AstraZeneca Goes Up Against 2 Cancer Upstarts", "Clovis Oncology (CLVS) Soars: Stock Adds 6.6% in Session", "Clovis (CLVS) Q4 Loss Narrower Than Expected, Revenues Miss", "Is a Surprise Coming for Clovis Oncology (CLVS) This Earnings Season?", "AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use", "Health Care Sector Update for 02/22/2018: CLVS,SGMO,GILD,BKD", "Health Care Sector Update for 02/22/2018: CLVS,SGMO,GILD,BKD", "Clovis Oncology Enters Oversold Territory (CLVS)", "AstraZeneca's Lynparza Now 'King' Of Its Class \u2014 Triumphing Over Tesaro", "AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan", "AstraZeneca's Lynparza Label Now Includes Breast Cancer", "Why These 3 Biotech Stocks Could Outperform Their Peers In 2018", "Health Care Sector Update for 02/22/2018: SGMO, GILD, CLVS, NVO, NVS, BKD", "Health Care Sector Update for 02/22/2018: CLVS,SGMO,GILD,BKD", "Clovis Up More Than 50% in 2017: What's Driving the Stock?", "Why These Biotech Stocks Could Be Taken Over In 2018", "Clovis Oncology Shows Rising Relative Strength; Still Shy Of Key Threshold", "Noteworthy Wednesday Option Activity: FNSR, CLVS, UAA", "Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study", "Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data", "Biotech Dives After Analyst Slashes Expectations For Cancer Drug", "These 2 European Pharmas Grabbed Upgrades Ahead Of 2018 News", "Clovis Up More Than 50% in 2017: What's Driving the Stock?", "Why These Biotech Stocks Could Be Taken Over In 2018", "Clovis Oncology Shows Rising Relative Strength; Still Shy Of Key Threshold", "Oversold Conditions For Clovis Oncology (CLVS)", "Notable Friday Option Activity: ICPT, GILD, CLVS", "Tesaro Takes A Swipe At AstraZeneca's Ovarian Cancer Drug Sales", "Clovis' sNDA for Rubraca Gets Priority Review in the U.S.", "Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down", "Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss", "Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?", "Neurocrine, Exelixis, Juno Stocks Rocket After Crushing Views", "Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?", "Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?", "Will Endocyte (ECYT) Disappoint This Earnings Season?", "Why Tesaro's $2 Million Cancer-Drug Miss Prompted Its Rivals To Topple", "What to Expect from Keryx (KERX) This Earnings Season?", "What's in Store for Intrexon (XON) This Earnings Season?", "Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?", "Is a Beat in Store for Zoetis (ZTS) This Earnings Season?", "Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?", "What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?", "What's in the Offing for Intercept (ICPT) in Q3 Earnings?", "Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?", "What to Expect from Keryx (KERX) This Earnings Season?", "What's in Store for Intrexon (XON) This Earnings Season?", "Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?", "What's in the Cards for Geron (GERN) this Earnings Season?", "What to Expect From Epizyme (EPZM) This Earnings Season?", "Allergan (AGN) to Report Q3 Earnings: What's in the Cards?", "Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus", "Is Aerie (AERI) Poised for a Beat This Earnings Season?", "Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?", "Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?", "AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review", "SPDR S&P Biotech ETF Experiences Big Outflow", "Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca", "XBI, CLVS, SRPT, PBYI: Large Inflows Detected at ETF", "These Biotechs Slump As Report Suggests Discounting Their Drugs", "XBI, ALNY, CLVS, SGEN: ETF Outflow Alert", "Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?", "TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion", "Health Care Sector Update for 09/18/2017: CLVS,LLY,ITUS,AEMD", "Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound?", "Why Clovis Oncology Fell 7.1% in August", "Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal", "Clovis Oncology Scores Relative Strength Rating Upgrade", "Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses", "Boxer Capital, LLC Buys Macrogenics Inc, G1 Therapeutics Inc, iPath S&P 500 VIX Short Term ...", "XBI, EXEL, ALXN, CLVS: ETF Outflow Alert", "Clovis Oncology Enters Oversold Territory (CLVS)", "Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses", "Why Clovis Oncology Tumbled 13.5% Today", "Here's Why Clovis Stock Is Up Almost 60% So Far in 2017", "AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion", "What's in the Cards for Merrimack (MACK) in Q2 Earnings?", "Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?", "What's in the Cards for Aerie (AERI) This Earnings Season?", "What's in Store for Endocyte (ECYT) this Earnings Season?", "XBI, CLVS, EXEL, ALXN: ETF Outflow Alert", "AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?", "Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today", "XBI, CLVS, EXEL, ALXN: Large Inflows Detected at ETF", "Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion", "Here's Why Clovis Oncology Inc. Jumped 70% in June", "Noteworthy ETF Outflows: XBI, CLVS, EXEL, ALXN", "3 Stocks That Turned $8,000 Into at Least $25,600 in Just One Year", "SPDR S&P Biotech ETF Experiences Big Inflow", "What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?", "3 Stocks at 52-Week Highs Still Worth Buying", "Healthcare ETF (IYH) Hits New 52-Week High", "3 Growth Stocks for Bright Investors", "Clovis Oncology, Inc. (CLVS) Worth a Look: Stock Jumps 6.3%", "Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study", "CLVS Crosses Above Average Analyst Target", "Why Clovis Oncology Inc (CLVS) Stock Just Shot 50% Higher", "Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?", "Why Tesaro Inc. Stock Briefly Dipped Today", "Why Clovis Oncology Stock Is Soaring Today", "Wall Street Sees Higher Open as Tech Sector Continues Recovery", "Pre-Market Most Active for Jun 19, 2017 : AEG, RICE, CLVS, AUY, QQQ, NVDQ, VRX, RIGL, HL, TSRO, KR, JD", "US Futures Nudge Higher as Tech Sector Extends Recovery", "Health Care Sector Update for 06/19/2017: CLVS,NVDQ,SYK,SGEN", "Clovis Oncology's Rubraca Notches Key Trial Win", "Here's Why Clovis Oncology (CLVS) Stock Skyrocketed Today", "Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year", "Surging Earnings Estimates Signal Good News for Clovis Oncology, Inc. (CLVS)", "3 Stocks Warren Buffett Can't Buy, but You Can", "Implied Volatility Surging for Clovis (CLVS) Stock Options", "Commit To Purchase Clovis Oncology At $40, Earn 24.8% Annualized Using Options", "Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain", "Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start", "Monday's ETF Movers: XBI, GDXJ", "Tesaro Inc Bulls Need a Reality Check", "Tesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing", "AbbVie's PARP Inhibitor Comes Up Empty", "3 Cancer Drug Stocks That Could Make You Rich", "Why Clovis Oncology's Stock Edged Higher in March", "AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA", "Tesaro Nets Surprise Early Approval", "Notable Wednesday Option Activity: CLVS, PRU, LITE", "Why Is Clovis (CLVS) Up 18.8% Since the Last Earnings Report?", "3 Stocks at 52-Week Highs Still Worth Buying", "Billionaires' Best Healthcare Stock Picks of 2017 (So Far)", "AstraZeneca Fires Back at Tesaro in Ovarian Cancer", "SPDR S&P Biotech ETF Experiences Big Inflow", "XBI, CLVS, KITE, TSRO: Large Inflows Detected at ETF", "Commit To Purchase Clovis Oncology At $35, Earn 12.3% Using Options", "Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula", "XBI, JPNL: Big ETF Outflows", "Noteworthy Friday Option Activity: SAGE, BAX, CLVS", "Boxer Capital, LLC Buys AveXis, BeiGene, Alnylam Pharmaceuticals, Sells Biomarin ...", "XBI, UGE: Big ETF Outflows", "3 Scorching Hot Biotech Stocks -- Are They Buys?", "Notable ETF Inflow Detected - XBI, CLVS, ACAD, UTHR", "3 Mid-Cap Biotech Stocks to Buy in February", "Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca", "Thursday's ETF with Unusual Volume: DWAS", "3 Biotechs Likely to Be Acquired in 2017", "What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?", "Thursday's ETF Movers: XBI, KRE", "The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals", "Clovis Declares Pricing of Upsized Offering of Common Stock", "Pre-Market Most Active for Jan 4, 2017 : BBVA, SMI, AZN, NVO, LYG, TOT, CLVS, NVDA, NVLS, TVIX, AAPL, QQQ", "Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher", "Christmas Came Early for These Biotech Stocks", "4 Stocks to Watch With Strong Technical Momentum", "Clovis Scales 52-Week High on Early FDA Nod for Rubraca", "Surprise! Clovis Oncology Nabs Early OK", "Stock Market Roundup, Dec. 19: GOOGL & BBRY Self-Driving Cars, CLVS Soars", "Here's Why Clovis Oncology (CLVS) Stock Is Soaring Today", "Short-Sellers Are Betting Big Against Clovis Oncology -- Here's Why They're Probably Right", "Biotech Stocks: What to Watch in 2017", "Here's Why These Biopharma Stocks Soared at Least 10% Today", "Clovis Oncology Reaches Analyst Target Price", "Why Clovis Oncology Inc. Rose 52.7% in September", "Tesaro Inc. Is Flying High Today (and Could Go Higher From Here)", "3 Cancer Drugs That Could Get an FDA OK Next Year", "Notable Friday Option Activity: CLVS, TSN, ANF", "Why Clovis Oncology Shares Are Falling 14.5% Today", "GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?", "5 Top Performing Stocks of the Best ETF of Q3", "Health Care Sector Update for 09/28/2016: CLVS, KPTI", "Moving Average Crossover Alert: Clovis Oncology (CLVS)", "3 Biotechs That Could Be M&A Targets", "Why Clovis Oncology Inc (CLVS), Philip Morris International Inc. (PM) And Weyerhaeuser Co (WY) Are 3 of Today\u2019s Best Stocks", "Stocks Futures Buoyed by Bank of Japan Move on Long-Term Rates; Waiting For FOMC", "Commit To Buy Clovis Oncology At $17.50, Earn 23.5% Annualized Using Options", "6 Best Performing Drug Stocks of September", "5 Top Performing Stocks of the Best ETF of Q3", "Is Clovis Oncology Still a Strong Buy?", "Clovis' Rucaparib Not to Face FDA Advisory Panel, Stock Up", "Clovis Oncology (CLVS) in Focus: Stock Moves 15% Higher", "Why Clovis Oncology Inc. Is Soaring Today", "Clovis Oncology Speeds Toward Possible Launch in Ovarian Cancer, but Red Flags Remain", "Health Care Sector Update for 08/31/2016: VEEV,CLVS,PFE", "Can The Uptrend Continue for Clovis Oncology (CLVS)?", "4 Momentum Stocks to Watch", "Is Clovis Oncology Still a Strong Buy?", "News, Good or Bad, Can Create Buying Opportunities", "Pre-Market Most Active for Aug 24, 2016 : ERIC, NVO, AZN, EXPR, CLVS, LYG, BCS, LDOS, QQQ, OSUR, GPRO, XIV", "Clovis (CLVS) Stock Up on FDA Priority Review for Rucaparib", "Why Best Buy Co Inc (BBY), Clovis Oncology Inc (CLVS) and Toll Brothers Inc (TOL) Are 3 of Today\u2019s Best Stocks", "Noteworthy Friday Option Activity: CLVS, FEYE, LVS", "Energy Sector Update for 08/31/2016: VEEV,CLVS,PFE", "Notable Friday Option Activity: QVCA, CLVS, HOS", "7 Biotech Stocks With Pivotal Catalysts in 2017", "Tuesday's ETF Movers: GDX, XBI", "The Math Shows IYH Can Go To $172", "3 Shocking Biotech Flops of 2016 So Far", "An Overnight Double! Could These Drugmakers Be Next?", "Clovis Oncology (CLVS) Jumps: Stock Adds 21.9% in Session", "Can The Uptrend Continue for Clovis Oncology (CLVS)?", "What's Causing Clovis Oncology Shares to Skyrocket Today?", "5 Reasons to Hate Biotech Stocks", "Investors Win When Boring Beats Sexy (XLU)", "Surprising Analyst 12-Month Target For IYH", "The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma", "Health Care Sector Update for 04/13/2016: APHB, RPRX, CLVS", "Biotech Stock Roundup: FDA Advisory Panels Say Yes to Intercept, No to Clovis", "Why Tesaro Inc (TSRO), Clovis Oncology Inc (CLVS) and Twilio Inc (TWLO) Are 3 of Today\u2019s Best Stocks", "Clovis Drops, FDA Panel Seeks More Data on Rociletinib", "Health Care Sector Update for 04/13/2016: PSTI,RPRX,CLVS", "Health Care Sector Update for 04/12/2016: AMGN, MRK, ABT, PFE, JNJ, CLVS, CBRP", "Why Horizon Pharma, Och-Ziff Capital Management, and Clovis Oncology Slumped Today", "Clovis Oncology's Failure Is a Big Win for AstraZeneca", "Health Care Sector Update for 04/12/2016: CLVS,CRBP,TTOO", "Clovis Hits 52-week Low Post Rociletinib Briefing Documents", "Why Clovis Oncology Inc (CLVS), Seagate Technology PLC (STX) and Sprint Corp (S) Are 3 of Today\u2019s Worst Stocks", "Clovis Drops, FDA Panel Seeks More Data on Rociletinib", "Clovis Oncology (CLVS) Catches Eye: Stock Moves 6% Higher", "Noteworthy Friday Option Activity: CLVS, TNET, CBM", "10 Biotech Stocks With Big Catalysts Coming This Quarter", "Sum Up The Pieces: IYH Could Be Worth $170", "Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now?", "The Zacks Analyst Blog Highlights: Incyte, Intercept Pharma, Gilead, Aegerion and Clovis", "Pre-Market Most Active for Apr 8, 2016 : TVIX, NOK, BAC, TOT, PBR, FCX, XIV, VRX, MRCY, CME, CLVS, QQQ", "Why Ruby Tuesday, Clovis Oncology, and G-III Apparel Group Slumped Today", "Implied RXL Analyst Target Price: $64", "Clovis (CLVS) Begins Immunotherapy Combination Study", "Commit To Purchase Clovis Oncology At $20, Earn 20% Using Options", "A Festivus for the Invest in Us -- It's Time for the Airing of Grievances", "The Zacks Analyst Blog Highlights: Amgen, ARIAD, Clovis Oncology, Regeneron and Akebia Therapeutics", "Clovis (CLVS) Rociletinib's Review Period Extended by FDA", "Clovis' (CLVS) Rociletinib to Face FDA Advisory Panel in April", "Why Shaken Confidence Caused Clovis Oncology, Inc. to Crash in November", "The Top 3 Drug Approvals of 2015", "Can AstraZeneca Live Up to Its $45 Billion Promise?", "Wednesday's ETF Movers: XBI, XOP", "Clovis: Execution Risk, Loss Of Credibility, & Regulatory Missteps Constrain Valuation", "Noteworthy Tuesday Option Activity: CLVS, ARIA, AJRD", "The Zacks Analyst Blog Highlights: Clovis Oncology, Gilead, AbbVie and Medicines Company", "Are These 3 Small-Cap Biotech Stocks Bargain-Bin Buys?", "Company News for November 17, 2015", "Pre-Market Most Active for Nov 17, 2015 : GE, SYF, SYF$, PSO, DKS, XIV, URBN, FIT, TVIX, FB, CLVS, QQQ", "Health Care Sector Update for 11/17/2015: CLVS, AZN, NVCR", "3 Stocks Wall Street Hates", "Why Clovis Oncology Inc Is Falling Again", "Clovis Crashes 70%, FDA Seeks More Data on Rociletinib", "Monday Sector Laggards: Apparel Stores, Drugs", "Clovis Oncology's Loss Could Be a Win for AstraZeneca", "Pre-Market Most Active for Nov 16, 2015 : GE, IBN, AZN, CNHI, TVIX, XIV, CLVS, AAPL, MAR, SUNE, QQQ, HOT", "Why Clovis Oncology, Dillard's, and Urban Outfitters Slumped Today", "Noteworthy Monday Option Activity: CLVS, MHLD, UNTD", "Monday's ETF Movers: XOP, XBI", "Clovis Posts Wider-than-Expected Loss in Q3, Shares Down", "Use Options For a Chance To Buy CLVS at a 45% Discount", "Interesting CLVS Put And Call Options For December 18th", "Here's Why Clovis Oncology's Stock Is Getting Pummeled Today", "Why This Biotech Stock Is Bucking Biotech's Bloodbath", "Use Options For a Chance To Buy CLVS at a 48% Discount", "Clovis' Rociletinib under Review in U.S., EU for Lung Cancer", "Interesting CLVS Put And Call Options For November 20th", "These Clinical-Stage Biotechs Could Be Ripe for a Takeover", "Clovis Oncology (CLVS) Jumps: Stock Adds 13.8% in Session", "Why Clovis Oncology Inc Shares Are Rocketing Higher Today", "3 Cancer Companies to Watch Closely in 2016", "Clovis Oncology Breaks Below 200-Day Moving Average - Notable for CLVS", "Clovis Oncology Strikes Deal with Roche for Rociletinib", "First Week of September 18th Options Trading For Clovis Oncology (CLVS)", "Use Options For a Chance To Buy CLVS at a 43% Discount", "Pre-Market Most Active for Jul 9, 2015 : GSK, NOK, XIV, AAPL, BAC, BABA, BP, AA, QQQ, TVIX, FB, CLVS", "Health Care Sector Update for 07/09/2015: CLVS,IPCI,AQXP", "Health Care Sector Update for 07/08/2015: CLVS,AEMD", "First Week of CLVS April 2016 Options Trading", "ImmunoGen Surges on Positive Ovarian Cancer Study Data - Analyst Blog", "Clovis Oncology (CLVS) Jumps: Stock Adds 16.7% in Session - Tale of the Tape", "Health Care Sector Update for 05/15/2015: CLVS,TCON,RKDA", "Clovis Oncology (CLVS) Falls: Stock Goes Down 5.3% - Tale of the Tape", "Why Clovis Oncology, Inc. Is Soaring Higher Today", "Monday's ETF Movers: XBI, GDXJ", "Clovis Oncology (CLVS) in Focus: Stock Moves 8% Higher - Tale of the Tape", "Clovis Oncology Starts Rolling NDA Submission for Rociletinib - Analyst Blog", "ImmunoGen Surges on Positive Ovarian Cancer Study Data - Analyst Blog", "Why Clovis Oncology Shares Soared Higher Today", "Health Care Sector Update for 04/07/2015: CLVS,BIND,OCUL", "Commit To Buy Clovis Oncology At $65, Earn 16.4% Annualized Using Options", "Clovis Oncology, Inc. (CLVS) in Focus: Stock Jumps 5.9% - Tale of the Tape", "AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog", "Clovis Oncology (CLVS) Shares Cross Below 200 DMA", "Tuesday's ETF Movers: XBI, GDX", "3 Beaten Down Biotech Stocks to Buy Now", "Big News for These 5 Stocks From ESMO", "CLVS January 2016 Options Begin Trading", "Clovis Oncology (CLVS) Falls: Stock Goes Down 6.8% - Tale of the Tape", "Sector Update: Health-Care Stocks Mixed Pre-Market", "Sector Update: Health Care", "Interesting CLVS Put And Call Options For August 16th", "AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog", "3 Beaten Down Biotech Stocks to Buy Now", "Clovis Oncology (CLVS) Jumps: Stock Rises 6.2% - Tale of the Tape", "Sector Update: Technology Shares Flat Pre-Market; Clovis Oncology Upgraded to Buy at Stifel Nicolaus", "Sector Update: Healthcare Healthcare", "Monday Sector Laggards: Drugs, Manufacturing Stocks", "Clovis Oncology (CLVS) Falls: Stock Goes Down 9.2% - Tale of the Tape", "Clovis Oncology Initiates Study on CO-1686 - Analyst Blog", "Healthcare Stocks Sputtering; Clovis Oncology Gaining After Cancer Treatment Wins Breakthrough Designation", "Sector Update: Healthcare", "Clovis Oncology, Inc. (CLVS) in Focus: Stock Surges 16 % - Tale of the Tape", "Friday's ETF Movers: VWO, XBI", "Sector Update: Healthcare", "Healthcare Stocks Sliding; Clovis Rallies After Posting Early Indications of Cancer Drug Success", "Sector Update: Healthcare Shares Flat Pre-Market; Baxter up 12% on Plans to Split Into 2 Companies", "Clovis Gets Breakthrough Therapy Designation - Analyst Blog", "Can The Uptrend Continue for Clovis Oncology Inc (CLVS)? - Tale of the Tape", "2013 in Review: The Good And The Bad", "Pre-Market Most Active for Dec 4, 2013 : JCP, EXPR, NOK, BAC, NCLH, QQQ, ALU, SAN, CCXI, TSLA, OMED, CLVS", "Sector Update: Healthcare", "Sector Update: Healthcare Shares Flat Pre-Market; Clovis Sinks 2% on Pricing Public Offering", "Sector Update: Healthcare Shares Flat Pre-Market; Drew Industries Net Income Rises Year-Over-Year", "Sector Update: Healthcare", "Sector Update: Healthcare", "3 Top Ranked Biotech Mutual Funds Surging Higher - Best of Funds", "US Futures Nearly Unchanged as Market Mulls Washington Budget, Debt Limit Risks", "US Futures Slightly Lower as Risk of Government Shutdown Looms", "Clovis Oncology (CLVS) Surges: Stock Gains 7.3% in Session - Analyst Blog", "Clovis / CO-1686: Value, Derived From Data, Supports The Valuation", "Pre-Market Most Active for Jun 12, 2013 : CTB, NCT, WDAY, BAC, VOD, S, NOK, GT, GRFS, ARNA, SIRI, CLVS", "Clovis Oncology (CLVS): A Love Story", "Clovis Sinks on Lack of Buyer Interest - Analyst Blog", "Pre-Market Most Active for Nov 12, 2012 : TIE, UN, BAC, GILD, MT, CLVS, FB, JEF, GRPN, DCM, NKTR, QQQ", "Mid-Afternoon Market Update: Markets Near Flat; J.C. Penney Falling Further", "Investing in Biotech Stocks? The Journey to Profits Requires a Good GPS", "Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes Lower"], "Elapsed Time": ["JUN 2, 2020", "MAY 28, 2020", "MAY 28, 2020", "MAY 19, 2020", "MAY 19, 2020", "MAY 18, 2020", "MAY 18, 2020", "MAY 16, 2020", "JUN 2, 2020", "MAY 15, 2020", "MAY 13, 2020", "MAY 12, 2020", "MAY 11, 2020", "MAY 7, 2020", "MAY 6, 2020", "APR 29, 2020", "MAY 15, 2020", "APR 27, 2020", "APR 20, 2020", "MAR 24, 2020", "MAR 9, 2020", "MAR 1, 2020", "FEB 25, 2020", "FEB 25, 2020", "APR 27, 2020", "FEB 24, 2020", "FEB 6, 2020", "FEB 5, 2020", "JAN 30, 2020", "JAN 15, 2020", "JAN 15, 2020", "JAN 15, 2020", "FEB 24, 2020", "JAN 9, 2020", "JAN 8, 2020", "JAN 7, 2020", "JAN 4, 2020", "DEC 17, 2019", "DEC 14, 2019", "DEC 13, 2019", "JAN 11, 2020", "JAN 9, 2020", "DEC 3, 2019", "DEC 3, 2019", "NOV 27, 2019", "NOV 25, 2019", "NOV 22, 2019", "NOV 13, 2019", "DEC 5, 2019", "OCT 28, 2019", "OCT 17, 2019", "OCT 13, 2019", "OCT 11, 2019", "OCT 11, 2019", "OCT 10, 2019", "SEP 24, 2019", "NOV 8, 2019", "OCT 28, 2019", "AUG 8, 2019", "AUG 2, 2019", "AUG 1, 2019", "APR 15, 2019", "APR 15, 2019", "APR 15, 2019", "SEP 4, 2019", "APR 15, 2019", "APR 15, 2019", "APR 15, 2019", "APR 12, 2019", "MAR 25, 2019", "FEB 28, 2019", "FEB 27, 2019", "APR 15, 2019", "FEB 27, 2019", "FEB 27, 2019", "FEB 21, 2019", "FEB 20, 2019", "FEB 20, 2019", "FEB 19, 2019", "FEB 19, 2019", "FEB 27, 2019", "FEB 27, 2019", "FEB 27, 2019", "FEB 21, 2019", "JAN 12, 2019", "JAN 11, 2019", "JAN 7, 2019", "DEC 27, 2018", "FEB 8, 2019", "DEC 20, 2018", "DEC 15, 2018", "DEC 14, 2018", "DEC 10, 2018", "DEC 8, 2018", "DEC 4, 2018", "DEC 4, 2018", "DEC 21, 2018", "DEC 4, 2018", "DEC 3, 2018", "NOV 29, 2018", "NOV 21, 2018", "NOV 21, 2018", "NOV 14, 2018", "NOV 13, 2018", "DEC 4, 2018", "NOV 2, 2018", "OCT 31, 2018", "OCT 31, 2018", "OCT 31, 2018", "OCT 31, 2018", "OCT 31, 2018", "OCT 30, 2018", "NOV 5, 2018", "NOV 2, 2018", "OCT 22, 2018", "OCT 19, 2018", "OCT 19, 2018", "OCT 19, 2018", "OCT 3, 2018", "OCT 3, 2018", "OCT 24, 2018", "OCT 2, 2018", "AUG 31, 2018", "AUG 15, 2018", "AUG 7, 2018", "AUG 3, 2018", "AUG 3, 2018", "JUL 17, 2018", "OCT 3, 2018", "JUL 6, 2018", "JUL 5, 2018", "JUN 27, 2018", "JUN 20, 2018", "JUN 19, 2018", "JUN 7, 2018", "JUN 4, 2018", "JUL 6, 2018", "MAY 9, 2018", "MAY 7, 2018", "APR 17, 2018", "APR 17, 2018", "APR 17, 2018", "APR 9, 2018", "APR 9, 2018", "MAY 30, 2018", "MAY 9, 2018", "MAR 27, 2018", "MAR 26, 2018", "MAR 9, 2018", "FEB 28, 2018", "FEB 27, 2018", "FEB 22, 2018", "APR 4, 2018", "FEB 22, 2018", "FEB 22, 2018", "FEB 8, 2018", "FEB 2, 2018", "JAN 22, 2018", "JAN 15, 2018", "JAN 5, 2018", "FEB 22, 2018", "FEB 22, 2018", "DEC 28, 2017", "DEC 19, 2017", "DEC 15, 2017", "DEC 13, 2017", "DEC 11, 2017", "DEC 6, 2017", "JAN 2, 2018", "DEC 29, 2017", "DEC 28, 2017", "DEC 19, 2017", "NOV 21, 2017", "NOV 17, 2017", "NOV 10, 2017", "NOV 9, 2017", "DEC 6, 2017", "NOV 7, 2017", "NOV 2, 2017", "NOV 1, 2017", "NOV 1, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 31, 2017", "NOV 8, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 31, 2017", "OCT 31, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 27, 2017", "OCT 27, 2017", "OCT 26, 2017", "OCT 26, 2017", "OCT 30, 2017", "OCT 23, 2017", "OCT 20, 2017", "OCT 19, 2017", "OCT 13, 2017", "OCT 10, 2017", "OCT 5, 2017", "OCT 3, 2017", "OCT 23, 2017", "OCT 23, 2017", "SEP 18, 2017", "SEP 18, 2017", "SEP 7, 2017", "SEP 7, 2017", "AUG 30, 2017", "SEP 28, 2017", "AUG 15, 2017", "AUG 14, 2017", "AUG 11, 2017", "AUG 9, 2017", "AUG 3, 2017", "JUL 31, 2017", "AUG 23, 2017", "AUG 18, 2017", "JUL 28, 2017", "JUL 27, 2017", "JUL 27, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 26, 2017", "JUL 31, 2017", "JUL 13, 2017", "JUL 13, 2017", "JUL 7, 2017", "JUL 5, 2017", "JUN 29, 2017", "JUN 27, 2017", "JUL 24, 2017", "JUL 18, 2017", "JUN 23, 2017", "JUN 23, 2017", "JUN 22, 2017", "JUN 20, 2017", "JUN 20, 2017", "JUN 19, 2017", "JUN 27, 2017", "JUN 19, 2017", "JUN 19, 2017", "JUN 19, 2017", "JUN 19, 2017", "JUN 19, 2017", "JUN 19, 2017", "JUN 19, 2017", "JUN 19, 2017", "JUN 16, 2017", "JUN 15, 2017", "JUN 12, 2017", "JUN 2, 2017", "MAY 26, 2017", "MAY 22, 2017", "MAY 4, 2017", "JUN 19, 2017", "APR 25, 2017", "APR 21, 2017", "APR 20, 2017", "APR 17, 2017", "APR 7, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAY 3, 2017", "MAR 28, 2017", "MAR 22, 2017", "MAR 21, 2017", "MAR 16, 2017", "MAR 14, 2017", "MAR 2, 2017", "FEB 23, 2017", "MAR 28, 2017", "FEB 22, 2017", "FEB 17, 2017", "FEB 16, 2017", "FEB 14, 2017", "FEB 8, 2017", "FEB 2, 2017", "JAN 29, 2017", "FEB 23, 2017", "JAN 26, 2017", "JAN 22, 2017", "JAN 17, 2017", "JAN 12, 2017", "JAN 10, 2017", "JAN 4, 2017", "JAN 4, 2017", "JAN 27, 2017", "DEC 21, 2016", "DEC 21, 2016", "DEC 20, 2016", "DEC 19, 2016", "DEC 19, 2016", "DEC 19, 2016", "DEC 13, 2016", "DEC 29, 2016", "NOV 9, 2016", "OCT 11, 2016", "OCT 10, 2016", "OCT 10, 2016", "OCT 9, 2016", "OCT 7, 2016", "OCT 7, 2016", "DEC 1, 2016", "SEP 30, 2016", "SEP 28, 2016", "SEP 26, 2016", "SEP 24, 2016", "SEP 22, 2016", "SEP 21, 2016", "SEP 20, 2016", "OCT 3, 2016", "SEP 13, 2016", "SEP 12, 2016", "SEP 9, 2016", "SEP 9, 2016", "SEP 8, 2016", "SEP 1, 2016", "AUG 31, 2016", "SEP 15, 2016", "SEP 13, 2016", "AUG 25, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 23, 2016", "AUG 19, 2016", "AUG 31, 2016", "AUG 5, 2016", "AUG 2, 2016", "AUG 2, 2016", "AUG 1, 2016", "JUL 8, 2016", "JUL 1, 2016", "JUN 30, 2016", "AUG 18, 2016", "JUN 29, 2016", "JUN 23, 2016", "JUN 21, 2016", "APR 19, 2016", "APR 14, 2016", "APR 13, 2016", "APR 13, 2016", "JUN 29, 2016", "APR 13, 2016", "APR 13, 2016", "APR 12, 2016", "APR 12, 2016", "APR 12, 2016", "APR 12, 2016", "APR 11, 2016", "APR 13, 2016", "APR 13, 2016", "APR 7, 2016", "APR 1, 2016", "MAR 31, 2016", "MAR 16, 2016", "MAR 15, 2016", "FEB 18, 2016", "APR 8, 2016", "APR 8, 2016", "FEB 10, 2016", "JAN 28, 2016", "JAN 7, 2016", "DEC 23, 2015", "DEC 17, 2015", "DEC 16, 2015", "FEB 15, 2016", "DEC 10, 2015", "DEC 8, 2015", "DEC 3, 2015", "DEC 2, 2015", "NOV 27, 2015", "NOV 24, 2015", "NOV 19, 2015", "DEC 13, 2015", "NOV 17, 2015", "NOV 17, 2015", "NOV 17, 2015", "NOV 17, 2015", "NOV 17, 2015", "NOV 17, 2015", "NOV 16, 2015", "NOV 19, 2015", "NOV 16, 2015", "NOV 16, 2015", "NOV 16, 2015", "NOV 16, 2015", "NOV 9, 2015", "NOV 2, 2015", "OCT 21, 2015", "NOV 16, 2015", "OCT 8, 2015", "OCT 2, 2015", "SEP 30, 2015", "SEP 24, 2015", "SEP 13, 2015", "SEP 10, 2015", "SEP 9, 2015", "OCT 20, 2015", "AUG 20, 2015", "AUG 12, 2015", "JUL 21, 2015", "JUL 14, 2015", "JUL 9, 2015", "JUL 9, 2015", "JUL 8, 2015", "AUG 28, 2015", "JUN 2, 2015", "MAY 15, 2015", "MAY 15, 2015", "APR 20, 2015", "APR 13, 2015", "APR 13, 2015", "APR 8, 2015", "JUL 2, 2015", "APR 7, 2015", "APR 7, 2015", "APR 7, 2015", "MAR 6, 2015", "JAN 14, 2015", "DEC 19, 2014", "NOV 17, 2014", "APR 7, 2015", "OCT 23, 2014", "SEP 30, 2014", "SEP 4, 2014", "SEP 4, 2014", "SEP 4, 2014", "SEP 4, 2014", "JUN 25, 2014", "OCT 27, 2014", "OCT 23, 2014", "JUN 6, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 2, 2014", "MAY 28, 2014", "JUN 24, 2014", "MAY 20, 2014", "MAY 20, 2014", "MAY 16, 2014", "MAY 16, 2014", "MAY 15, 2014", "MAY 15, 2014", "MAR 27, 2014", "MAY 22, 2014", "JAN 10, 2014", "DEC 27, 2013", "DEC 4, 2013", "DEC 4, 2013", "DEC 4, 2013", "NOV 1, 2013", "NOV 1, 2013", "MAR 27, 2014", "SEP 26, 2013", "SEP 25, 2013", "SEP 25, 2013", "SEP 18, 2013", "JUN 12, 2013", "JUN 12, 2013", "MAR 14, 2013", "SEP 26, 2013", "NOV 12, 2012", "NOV 12, 2012", "AUG 31, 2012", "NOV 12, 2012"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/is-acadia-pharmaceuticals-a-buy-2020-06-02", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-arca-biopharma-aerpio-pharma-triumph-group-2020-05-28", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-blue-hat-arca-biopharma-aerpio-pharma-2020-05-28", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-xenetic-biosciences-dycom-dynavax-technologies-2020-05-19", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-dynavax-technologies-arbutus-biopharama-flotek-2020-05-19", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-centric-brands-fulgent-genetics-moderna-2020-05-18-0", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-centric-brands-fulgent-genetics-moderna-2020-05-18", "https://www.nasdaq.com/articles/clovis-oncology-secures-fda-approval-for-rubraca-in-prostate-cancer-2020-05-16", "https://www.nasdaq.com/articles/is-acadia-pharmaceuticals-a-buy-2020-06-02", "https://www.nasdaq.com/articles/clovis-oncologys-rubraca-gets-u.s.-fda-approval-for-prostate-cancer-2020-05-15", "https://www.nasdaq.com/articles/5-top-stock-trades-for-thursday%3A-aapl-spy-wfc-clvs-save-2020-05-13", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-clvs-spg-aap-2020-05-12", "https://www.nasdaq.com/articles/why-clovis-oncology-stock-marched-higher-in-april-2020-05-11", "https://www.nasdaq.com/articles/from-gilead-to-astrazeneca-investors-should-watch-these-biotech-giants-right-now-2020-05", "https://www.nasdaq.com/articles/clovis-oncology-clvs-q1-2020-earnings-call-transcript-2020-05-06", "https://www.nasdaq.com/articles/u.s.-fda-gives-broader-approval-to-gsks-zejula-for-ovarian-cancer-2020-04-29", "https://www.nasdaq.com/articles/clovis-oncologys-rubraca-gets-u.s.-fda-approval-for-prostate-cancer-2020-05-15-0", "https://www.nasdaq.com/articles/positive-prostate-cancer-results-for-lynparza-are-bad-news-for-clovis-oncology-2020-04-27", "https://www.nasdaq.com/articles/why-clovis-oncology-immunomedics-and-puma-biotechnology-all-spiked-today-2020-04-20", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-mcd-hd-clvs-2020-03-24", "https://www.nasdaq.com/articles/why-clovis-oncology-stock-is-tanking-today-2020-03-09", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-has-upside-potential-in-2020-2020-03-01", "https://www.nasdaq.com/articles/whats-behind-clovis-oncologys-mixed-q4-results-2020-02-25", "https://www.nasdaq.com/articles/clovis-oncology-clvs-q4-2019-earnings-call-transcript-2020-02-25", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-may-2020-2020-04-27", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-lost-as-much-as-11.8-today-2020-02-24", "https://www.nasdaq.com/articles/4-stocks-looking-higher-2020-02-06", "https://www.nasdaq.com/articles/why-clovis-oncology-stock-is-popping-today-2020-02-05", "https://www.nasdaq.com/articles/2-incredibly-cheap-cancer-stocks-to-buy-now-2020-01-30", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-clvs-okta-ttd-2020-01-15", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-rose-as-much-as-25.6-today-2020-01-15", "https://www.nasdaq.com/articles/fda-gives-clovis-oncologys-rubraca-a-priority-review-2020-01-15", "https://www.nasdaq.com/articles/clovis-oncologys-sales-growth-slows-in-q4-2020-02-24", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-stock-sank-41.9-in-2019-2020-01-09", "https://www.nasdaq.com/articles/fda-nod-for-mrk-all-eyes-on-agtc-action-boosts-aplt-2020-01-08", "https://www.nasdaq.com/articles/clovis-oncology-reports-preliminary-fourth-quarter-sales-of-rubraca-and-sells-additional", "https://www.nasdaq.com/articles/3-top-biotech-stocks-to-buy-in-january-2020-01-04", "https://www.nasdaq.com/articles/why-clovis-oncology-stock-is-sinking-today-2019-12-17", "https://www.nasdaq.com/articles/are-these-biotech-companies-buyout-candidates-deal-or-no-deal-2019-12-14", "https://www.nasdaq.com/articles/this-pharma-stock-soared-more-than-360-in-november-2019-12-13", "https://www.nasdaq.com/articles/all-the-2020-pre-jpm-news-healthcare-investors-need-to-know-2020-01-11", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-stock-sank-41.9-in-2019-2020-01-09", "https://www.nasdaq.com/articles/is-clovis-oncology-really-a-buyout-candidate-2019-12-03", "https://www.nasdaq.com/articles/3-top-growth-stocks-to-buy-in-december-2019-12-03", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-dxcm-expe-clvs-2019-11-27", "https://www.nasdaq.com/articles/the-return-of-ma-activity-is-lifting-these-biotech-stocks-today-2019-11-25", "https://www.nasdaq.com/articles/these-3-value-stocks-are-absurdly-cheap-right-now-2019-11-22", "https://www.nasdaq.com/articles/todays-top-5-gainers-in-healthcare-sector-idya-elmd-clbs...-2019-11-13", "https://www.nasdaq.com/articles/thursdays-etf-movers%3A-cqqq-ibb-2019-12-05", "https://www.nasdaq.com/articles/top-6-gainers-in-healthcare-sector-today-crvs-clvs-tgtx...-2019-10-28", "https://www.nasdaq.com/articles/todays-top-5-gainers-in-healthcare-sector-hepa-endp-clvs...-2019-10-17", "https://www.nasdaq.com/articles/3-beaten-up-biotechs-are-they-buys-2019-10-13", "https://www.nasdaq.com/articles/health-care-sector-update-for-10-11-2019%3A-clvsgernacrshexohexo.to-2019-10-11", "https://www.nasdaq.com/articles/will-the-pace-of-ma-pick-up-following-the-biotech-sectors-pounding-2019-10-11", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-to-buy-right-now-2019-10-10", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-fell-as-much-as-13.5-today-2019-09-24", "https://www.nasdaq.com/articles/clovis-oncology-clvs-q3-2019-earnings-call-transcript-2019-11-08", "https://www.nasdaq.com/articles/thursday-8-22-insider-buying-report%3A-mmp-clvs-2019-08-22", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-vra-clvs-tsco-2019-08-08", "https://www.nasdaq.com/articles/clovis-oncology-clvs-q2-2019-earnings-call-transcript-2019-08-02", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-stock-fell-as-much-as-15.6-today-2019-08-01", "https://www.nasdaq.com/articles/clovis-oncology-news-clvs-stock-sinks-trial-cancer-treatment-2019-04-15", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-stock-dropped-much-13-today-2019-04-15", "https://www.nasdaq.com/articles/notable-monday-option-activity-hri-espr-clvs-2019-04-15", "https://www.nasdaq.com/articles/near-an-all-time-low-is-clovis-oncology-a-buy-2019-09-04", "https://www.nasdaq.com/articles/clovis-oncology-news-clvs-stock-sinks-trial-cancer-treatment-2019-04-15-0", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-stock-dropped-much-13-today-2019-04-15-0", "https://www.nasdaq.com/articles/notable-monday-option-activity-hri-espr-clvs-2019-04-15-0", "https://www.nasdaq.com/articles/clovis-oncology-halts-mid-stage-bladder-cancer-trial-shares-drop-2019-04-12", "https://www.nasdaq.com/articles/clovis-oncology-enters-oversold-territory-clvs-2019-03-25", "https://www.nasdaq.com/articles/clvs-crosses-above-key-moving-average-level-2019-02-28", "https://www.nasdaq.com/articles/clovis-oncology-inc-clvs-q4-2018-earnings-conference-call-transcript-2019-02-27", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-15-2019%3A-asmb-apha-clvs-jnj-pfe-mrk-abt-amgn-2019-04-15", "https://www.nasdaq.com/articles/astrazeneca-mercks-lynparza-meets-endpoint-in-polo-study-2019-02-27", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-stock-jumped-wednesday-2019-02-27", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-intercept-gilead-vertex-alkermes-and-clovis-2019-02-21", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-icpt-strong-on-nash-drug-data-collaborations-more-2019-02-20", "https://www.nasdaq.com/articles/is-the-options-market-predicting-a-spike-in-clovis-oncology-clvs-stock-2019-02-20", "https://www.nasdaq.com/articles/consumer-sector-update-02192019-morcndticptclvsalks-2019-02-19", "https://www.nasdaq.com/articles/health-care-sector-update-02192019-cndticptclvsalks-2019-02-19", "https://www.nasdaq.com/articles/clovis-clvs-q4-earnings-lag-estimates-rubraca-sales-recover-2019-02-27", "https://www.nasdaq.com/articles/astrazeneca-mercks-lynparza-meets-endpoint-in-polo-study-2019-02-27", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-stock-jumped-wednesday-2019-02-27", "https://www.nasdaq.com/articles/immunomedics-gets-crl-from-fda-for-breast-cancer-candidate-2019-01-18", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2019-01-12", "https://www.nasdaq.com/articles/implied-volatility-surging-for-clovis-oncology-clvs-stock-options-2019-01-11", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-rose-much-219-today-2019-01-07", "https://www.nasdaq.com/articles/immunomedics-enters-into-supply-deal-for-breast-cancer-drug-2018-12-27", "https://www.nasdaq.com/articles/notable-friday-option-activity-cara-clvs-tcx-2019-02-08", "https://www.nasdaq.com/articles/astrazenecas-azn-lynparza-gets-fda-nod-in-1st-line-setting-2018-12-20", "https://www.nasdaq.com/articles/3-biotechs-gilead-sciences-could-buy-march-2018-12-15", "https://www.nasdaq.com/articles/do-options-traders-know-something-about-clovis-clvs-stock-we-dont-2018-12-14", "https://www.nasdaq.com/articles/clovis-oncology-clvs-in-focus%3A-stock-moves-6.9-higher-2018-12-10", "https://www.nasdaq.com/articles/could-these-be-next-2-biotech-buyouts-2018-12-08", "https://www.nasdaq.com/articles/health-care-sector-update-12042018-clvs-cron-mo-psti-jnj-pfe-mrk-abt-amgn-2018-12-04", "https://www.nasdaq.com/articles/glaxo-to-buy-zejula-maker-tesaro-for-%245.1b-stock-down-8-2018-12-04", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-clvs-abbv-aal-2018-12-21", "https://www.nasdaq.com/articles/health-care-sector-update-12042018-gernclvspsti-2018-12-04", "https://www.nasdaq.com/articles/why-glaxosmithkline-clovis-oncology-and-tesaro-are-move-today-2018-12-03", "https://www.nasdaq.com/articles/clovis-clvs-up-45.1-since-last-earnings-report%3A-can-it-continue-2018-11-29", "https://www.nasdaq.com/articles/clovis-clvs-rubraca-gets-another-us-patent-shares-up-2018-11-21", "https://www.nasdaq.com/articles/tesaro-shares-rally-on-rumors-of-potential-acquisition-offer-2018-11-21", "https://www.nasdaq.com/articles/tesaro-clovis-rally-on-fda-priority-review-for-lynparza-snda-2018-11-14", "https://www.nasdaq.com/articles/astrazenecas-lynparza-gets-priority-review-in-1st-line-use-2018-11-13", "https://www.nasdaq.com/articles/tesaro-shares-rally-on-glaxos-%245.1-billion-buyout-offer-2018-12-04", "https://www.nasdaq.com/articles/tesaro-tsro-q3-earnings-beat-revenues-miss-shares-up-2018-11-02", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-got-crushed-today-2018-10-31", "https://www.nasdaq.com/articles/clovis-clvs-q3-earnings-sales-lag-rubraca-disappoints-2018-10-31", "https://www.nasdaq.com/articles/health-care-sector-update-10312018-clvs-exas-sny-jnj-pfe-abt-mrk-amgn-2018-10-31", "https://www.nasdaq.com/articles/health-care-sector-update-10312018-icptnuvaexasclvs-2018-10-31", "https://www.nasdaq.com/articles/health-care-sector-update-10312018-nuvaexasclvs-2018-10-31", "https://www.nasdaq.com/articles/clovis-oncology-clvs-reports-q3-loss-misses-revenue-estimates-2018-10-30", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-stock-dropped-whopping-604-october-2018-11-05", "https://www.nasdaq.com/articles/tesaro-tsro-q3-earnings-beat-revenues-miss-shares-up-2018-11-02", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-dropped-much-212-today-2018-10-22", "https://www.nasdaq.com/articles/health-care-sector-update-10192018-avxl-vlrx-clvs-jnj-pfe-abt-mrk-amgn-2018-10-19", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-inc-losing-ground-today-2018-10-19", "https://www.nasdaq.com/articles/health-care-sector-update-10192018-mack-avxl-clvs-jnj-pfe-abt-mrk-amgn-2018-10-19", "https://www.nasdaq.com/articles/clovis-rubraca-gets-breakthrough-therapy-status-for-mcrpc-2018-10-03", "https://www.nasdaq.com/articles/company-news-for-oct-3-2018-2018-10-03", "https://www.nasdaq.com/articles/heres-why-tesaro-inc-dropped-138-today-2018-10-24", "https://www.nasdaq.com/articles/mid-afternoon-market-update-stitch-fix-falls-after-q4-results-pyxus-international-shares", "https://www.nasdaq.com/articles/why-is-clovis-clvs-down-12.9-since-last-earnings-report-2018-08-31", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-clvs-utx-axdx-2018-08-15", "https://www.nasdaq.com/articles/interesting-clvs-put-and-call-options-november-16th-2018-08-07", "https://www.nasdaq.com/articles/clovis-clvs-q2-loss-wider-than-expected-revenues-beat-2018-08-03", "https://www.nasdaq.com/articles/tesaro-tsro-misses-earnings-and-revenue-estimates-in-q2-2018-08-03", "https://www.nasdaq.com/articles/iyhs-holdings-imply-11-gain-potential-2018-07-17", "https://www.nasdaq.com/articles/implied-volatility-surging-for-clovis-oncology-clvs-stock-options-2018-10-03", "https://www.nasdaq.com/articles/implied-volatility-surging-for-clovis-oncology-clvs-stock-options-2018-07-06", "https://www.nasdaq.com/articles/health-care-sector-update-07052018-clvsapopazrxzyne-2018-07-05", "https://www.nasdaq.com/articles/astrazeneca-mercks-lynparza-betters-survival-in-phase-iii-2018-06-27", "https://www.nasdaq.com/articles/interesting-clvs-put-and-call-options-august-17th-2018-06-20", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-mgm-clvs-gbt-2018-06-19", "https://www.nasdaq.com/articles/clovis-oncology-clvs-up-11.5-since-earnings-report%3A-can-it-continue-2018-06-07", "https://www.nasdaq.com/articles/why-fossil-group-companhia-siderurgica-nacional-and-immunomedics-jumped-today-2018-06-04", "https://www.nasdaq.com/articles/clovis-gets-eu-acceptance-for-rubraca-label-expansion-filing-2018-07-06", "https://www.nasdaq.com/articles/clovis-clvs-q1-loss-wider-than-expected-revenues-beat-2018-05-09", "https://www.nasdaq.com/articles/whats-in-store-for-horizon-pharma-hznp-in-q1-earnings-2018-05-07", "https://www.nasdaq.com/articles/health-care-sector-update-04172018-jnj-arql-avxl-nvcr-clvs-2018-04-17", "https://www.nasdaq.com/articles/health-care-sector-update-04172018-arqlncvrjnjclvs-2018-04-17", "https://www.nasdaq.com/articles/health-care-sector-update-04172018-nvcrjnjclvs-2018-04-17", "https://www.nasdaq.com/articles/clovis-clvs-rubraca-gets-fda-nod-as-maintainence-therapy-2018-04-09", "https://www.nasdaq.com/articles/clovis-oncology-clvs-surges%3A-stock-moves-5.9-higher-2018-04-09", "https://www.nasdaq.com/articles/clovis-rubraca-gets-approval-in-europe-for-ovarian-cancer-2018-05-30", "https://www.nasdaq.com/articles/clovis-clvs-q1-loss-wider-than-expected-revenues-beat-2018-05-09", "https://www.nasdaq.com/articles/tesaro-wants-stronger-grip-ovarian-cancer-2018-03-27", "https://www.nasdaq.com/articles/clovis-gets-positive-chmp-opinion-for-ovarian-cancer-drug-2018-03-26", "https://www.nasdaq.com/articles/astrazeneca-goes-against-2-cancer-upstarts-2018-03-09", "https://www.nasdaq.com/articles/clovis-oncology-clvs-soars%3A-stock-adds-6.6-in-session-2018-02-28", "https://www.nasdaq.com/articles/clovis-clvs-q4-loss-narrower-than-expected-revenues-miss-2018-02-27", "https://www.nasdaq.com/articles/is-a-surprise-coming-for-clovis-oncology-clvs-this-earnings-season-2018-02-22", "https://www.nasdaq.com/articles/astrazenecas-azn-bydureon-gets-fda-nod-for-expanded-use-2018-04-04", "https://www.nasdaq.com/articles/health-care-sector-update-02222018-clvssgmogildbkd-2018-02-22-0", "https://www.nasdaq.com/articles/health-care-sector-update-02222018-clvssgmogildbkd-2018-02-22", "https://www.nasdaq.com/articles/clovis-oncology-enters-oversold-territory-clvs-2018-02-08", "https://www.nasdaq.com/articles/astrazenecas-lynparza-now-king-its-class-triumphing-over-tesaro-2018-02-02", "https://www.nasdaq.com/articles/astrazenecas-parp-inhibitor-lynparza-gets-approval-in-japan-2018-01-22", "https://www.nasdaq.com/articles/astrazenecas-lynparza-label-now-includes-breast-cancer-2018-01-15", "https://www.nasdaq.com/articles/why-these-3-biotech-stocks-could-outperform-their-peers-2018-2018-01-05", "https://www.nasdaq.com/articles/health-care-sector-update-02222018-sgmo-gild-clvs-nvo-nvs-bkd-2018-02-22", "https://www.nasdaq.com/articles/these-2-european-pharmas-grabbed-upgrades-ahead-2018-news-2017-12-29", "https://www.nasdaq.com/articles/clovis-up-more-than-50-in-2017%3A-whats-driving-the-stock-2017-12-28", "https://www.nasdaq.com/articles/why-these-biotech-stocks-could-be-taken-over-2018-2017-12-19", "https://www.nasdaq.com/articles/clovis-oncology-shows-rising-relative-strength-still-shy-key-threshold-2017-12-15", "https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-fnsr-clvs-uaa-2017-12-13", "https://www.nasdaq.com/articles/pfizers-pfe-talazoparib-emerges-superior-in-embraca-study-2017-12-11", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-amgen-pcsk9-inhibitor-revance-rt002-data-2017-12-06", "https://www.nasdaq.com/articles/biotech-dives-after-analyst-slashes-expectations-cancer-drug-2018-01-02", "https://www.nasdaq.com/articles/these-2-european-pharmas-grabbed-upgrades-ahead-2018-news-2017-12-29", "https://www.nasdaq.com/articles/clovis-up-more-than-50-in-2017%3A-whats-driving-the-stock-2017-12-28", "https://www.nasdaq.com/articles/why-these-biotech-stocks-could-be-taken-over-2018-2017-12-19", "https://www.nasdaq.com/articles/tesaro-tsro-ovarian-cancer-drug-zejula-gets-approval-in-eu-2017-11-21", "https://www.nasdaq.com/articles/oversold-conditions-clovis-oncology-clvs-2017-11-17", "https://www.nasdaq.com/articles/notable-friday-option-activity-icpt-gild-clvs-2017-11-10", "https://www.nasdaq.com/articles/tesaro-takes-swipe-astrazenecas-ovarian-cancer-drug-sales-2017-11-09", "https://www.nasdaq.com/articles/clovis-snda-for-rubraca-gets-priority-review-in-the-u.s.-2017-12-06", "https://www.nasdaq.com/articles/nektar-acadia-pop-street-crushing-quarters-tesaro-dips-2017-11-07", "https://www.nasdaq.com/articles/clovis-clvs-q3-loss-wider-than-expected-revenues-miss-2017-11-02", "https://www.nasdaq.com/articles/celldex-cldx-to-report-q3-earnings%3A-whats-in-the-cards-2017-11-01", "https://www.nasdaq.com/articles/neurocrine-exelixis-juno-stocks-rocket-after-crushing-views-2017-11-01", "https://www.nasdaq.com/articles/is-aveo-pharmaceuticals-poised-for-a-beat-in-q3-earnings-2017-10-31", "https://www.nasdaq.com/articles/is-acadia-acad-likely-to-beat-earnings-estimates-in-q3-2017-10-31", "https://www.nasdaq.com/articles/will-endocyte-ecyt-disappoint-this-earnings-season-2017-10-31", "https://www.nasdaq.com/articles/why-tesaros-2-million-cancer-drug-miss-prompted-its-rivals-topple-2017-11-08", "https://www.nasdaq.com/articles/what-to-expect-from-keryx-kerx-this-earnings-season-2017-10-31", "https://www.nasdaq.com/articles/whats-in-store-for-intrexon-xon-this-earnings-season-2017-10-31", "https://www.nasdaq.com/articles/spectrum-pharmaceuticals-sppi-q3-earnings%3A-whats-in-store-2017-10-31", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-zoetis-zts-this-earnings-season-2017-10-30", "https://www.nasdaq.com/articles/is-a-turnaround-in-store-for-teva-teva-in-q3-earnings-2017-10-30", "https://www.nasdaq.com/articles/whats-in-the-cards-for-immune-design-imdz-in-q3-earnings-2017-10-30", "https://www.nasdaq.com/articles/whats-in-the-offing-for-intercept-icpt-in-q3-earnings-2017-10-30", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q3-earnings%3A-a-beat-in-store-2017-10-31", "https://www.nasdaq.com/articles/what-to-expect-from-keryx-kerx-this-earnings-season-2017-10-31", "https://www.nasdaq.com/articles/whats-in-the-cards-for-arena-arna-this-earnings-season-2017-10-30", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-immunogen-imgn-in-q3-earnings-2017-10-30", "https://www.nasdaq.com/articles/whats-in-the-cards-for-geron-gern-this-earnings-season-2017-10-27", "https://www.nasdaq.com/articles/what-to-expect-from-epizyme-epzm-this-earnings-season-2017-10-27", "https://www.nasdaq.com/articles/allergan-agn-to-report-q3-earnings%3A-whats-in-the-cards-2017-10-26", "https://www.nasdaq.com/articles/bristol-myers-bmy-misses-on-q3-earnings-opdivo-in-focus-2017-10-26", "https://www.nasdaq.com/articles/is-aerie-aeri-poised-for-a-beat-this-earnings-season-2017-10-30", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-bristol-myers-bmy-in-q3-earnings-2017-10-23", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-vertex-vrtx-in-q3-earnings-2017-10-20", "https://www.nasdaq.com/articles/astrazenecas-snda-for-two-cancer-drugs-gets-priority-review-2017-10-19", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2017-10-13", "https://www.nasdaq.com/articles/clovis-clvs-submits-snda-for-ovarian-cancer-drug-rubraca-2017-10-10", "https://www.nasdaq.com/articles/xbi-clvs-srpt-pbyi-large-inflows-detected-etf-2017-10-05", "https://www.nasdaq.com/articles/these-biotechs-slump-report-suggests-discounting-their-drugs-2017-10-03", "https://www.nasdaq.com/articles/xbi-alny-clvs-sgen-etf-outflow-alert-2017-10-23", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-bristol-myers-bmy-in-q3-earnings-2017-10-23", "https://www.nasdaq.com/articles/tesaro-ovarian-cancer-drug-zejula-gets-positive-chmp-opinion-2017-09-18", "https://www.nasdaq.com/articles/health-care-sector-update-09182017-clvsllyitusaemd-2017-09-18", "https://www.nasdaq.com/articles/clovis-clvs-down-8.1-since-earnings-report%3A-can-it-rebound-2017-09-07", "https://www.nasdaq.com/articles/why-clovis-oncology-fell-71-august-2017-09-07", "https://www.nasdaq.com/articles/juno-bluebird-hot-acquisition-targets-after-kite-gilead-deal-2017-08-30", "https://www.nasdaq.com/articles/clovis-oncology-scores-relative-strength-rating-upgrade-2017-09-28", "https://www.nasdaq.com/articles/clovis-clvs-focuses-on-label-expansion-rubraca-impresses-2017-08-15", "https://www.nasdaq.com/articles/boxer-capital-llc-buys-macrogenics-inc-g1-therapeutics-inc-ipath-sp-500-vix-short-term", "https://www.nasdaq.com/articles/xbi-exel-alxn-clvs-etf-outflow-alert-2017-08-11", "https://www.nasdaq.com/articles/clovis-oncology-enters-oversold-territory-clvs-2017-08-09", "https://www.nasdaq.com/articles/clovis-clvs-q2-loss-wider-than-expected-rubraca-impresses-2017-08-03", "https://www.nasdaq.com/articles/why-clovis-oncology-tumbled-135-today-2017-07-31", "https://www.nasdaq.com/articles/heres-why-clovis-stock-is-up-almost-60-so-far-in-2017-2017-08-23", "https://www.nasdaq.com/articles/astrazeneca-mercks-lynparza-gets-fda-nod-for-label-expansion-2017-08-18", "https://www.nasdaq.com/articles/whats-in-the-cards-for-merrimack-mack-in-q2-earnings-2017-07-28", "https://www.nasdaq.com/articles/can-biomarin-bmrn-keep-the-earnings-streak-alive-in-q2-2017-07-27", "https://www.nasdaq.com/articles/whats-in-the-cards-for-aerie-aeri-this-earnings-season-2017-07-27", "https://www.nasdaq.com/articles/whats-in-store-for-endocyte-ecyt-this-earnings-season-2017-07-26", "https://www.nasdaq.com/articles/xbi-clvs-exel-alxn-etf-outflow-alert-2017-07-26", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-q2-earnings%3A-whats-in-store-2017-07-26", "https://www.nasdaq.com/articles/why-clovis-oncology-gulfport-energy-and-hertz-global-holdings-slumped-today-2017-07-31", "https://www.nasdaq.com/articles/xbi-clvs-exel-alxn-large-inflows-detected-etf-2017-07-13", "https://www.nasdaq.com/articles/clovis-clvs-focuses-on-rubraca-launch-and-label-expansion-2017-07-13", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-inc-jumped-70-june-2017-07-07", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xbi-clvs-exel-alxn-2017-07-05", "https://www.nasdaq.com/articles/3-stocks-turned-8000-least-25600-just-one-year-2017-06-29", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-inflow-2017-06-27", "https://www.nasdaq.com/articles/whats-in-the-cards-for-merck-kgaa-mkgaf-in-q2-earnings-2017-07-24", "https://www.nasdaq.com/articles/3-stocks-52-week-highs-still-worth-buying-2017-07-18", "https://www.nasdaq.com/articles/healthcare-etf-iyh-hits-new-52-week-high-2017-06-23", "https://www.nasdaq.com/articles/3-growth-stocks-bright-investors-2017-06-23", "https://www.nasdaq.com/articles/clovis-oncology-inc.-clvs-worth-a-look%3A-stock-jumps-6.3-2017-06-22", "https://www.nasdaq.com/articles/clovis-up-nearly-50-on-solid-data-from-ovarian-cancer-study-2017-06-20", "https://www.nasdaq.com/articles/clvs-crosses-above-average-analyst-target-2017-06-20", "https://www.nasdaq.com/articles/why-clovis-oncology-inc-clvs-stock-just-shot-50-higher-2017-06-19", "https://www.nasdaq.com/articles/will-abbvie-outsmart-biosimilars-and-can-clovis-win-parp-race-2017-06-27", "https://www.nasdaq.com/articles/why-tesaro-inc-stock-briefly-dipped-today-2017-06-19", "https://www.nasdaq.com/articles/why-clovis-oncology-stock-soaring-today-2017-06-19", "https://www.nasdaq.com/articles/wall-street-sees-higher-open-tech-sector-continues-recovery-2017-06-19", "https://www.nasdaq.com/articles/pre-market-most-active-jun-19-2017-aeg-rice-clvs-auy-qqq-nvdq-vrx-rigl-hl-tsro-kr-jd-2017", "https://www.nasdaq.com/articles/us-futures-nudge-higher-tech-sector-extends-recovery-2017-06-19", "https://www.nasdaq.com/articles/health-care-sector-update-06192017-clvsnvdqsyksgen-2017-06-19", "https://www.nasdaq.com/articles/clovis-oncologys-rubraca-notches-key-trial-win-2017-06-19", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-clvs-stock-skyrocketed-today-2017-06-19", "https://www.nasdaq.com/articles/heres-why-clovis-clvs-stock-is-up-almost-350-in-one-year-2017-06-16", "https://www.nasdaq.com/articles/surging-earnings-estimates-signal-good-news-for-clovis-oncology-inc.-clvs-2017-06-15", "https://www.nasdaq.com/articles/3-stocks-warren-buffett-cant-buy-you-can-2017-06-12", "https://www.nasdaq.com/articles/implied-volatility-surging-for-clovis-clvs-stock-options-2017-06-02", "https://www.nasdaq.com/articles/commit-purchase-clovis-oncology-40-earn-248-annualized-using-options-2017-05-26", "https://www.nasdaq.com/articles/clovis-clvs-parp-inhibtor-shows-promise-risks-remain-2017-05-22", "https://www.nasdaq.com/articles/clovis-clvs-q1-loss-narrows-rubraca-off-to-a-good-start-2017-05-04", "https://www.nasdaq.com/articles/mondays-etf-movers-xbi-gdxj-2017-06-19", "https://www.nasdaq.com/articles/tesaro-inc-bulls-need-reality-check-2017-04-25", "https://www.nasdaq.com/articles/tesaros-path-billion-dollar-blockbuster-begins-pricing-2017-04-21", "https://www.nasdaq.com/articles/abbvies-parp-inhibitor-comes-empty-2017-04-20", "https://www.nasdaq.com/articles/3-cancer-drug-stocks-could-make-you-rich-2017-04-17", "https://www.nasdaq.com/articles/why-clovis-oncologys-stock-edged-higher-march-2017-04-07", "https://www.nasdaq.com/articles/astrazenecas-azn-lynparza-nda-accepted-for-review-by-fda-2017-03-29", "https://www.nasdaq.com/articles/tesaro-nets-surprise-early-approval-2017-03-29", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-clvs-pru-lite-2017-05-03", "https://www.nasdaq.com/articles/why-is-clovis-clvs-up-18.8-since-the-last-earnings-report-2017-03-28", "https://www.nasdaq.com/articles/3-stocks-52-week-highs-still-worth-buying-2017-03-22", "https://www.nasdaq.com/articles/billionaires-best-healthcare-stock-picks-2017-so-far-2017-03-21", "https://www.nasdaq.com/articles/astrazeneca-fires-back-tesaro-ovarian-cancer-2017-03-16", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-inflow-2017-03-14", "https://www.nasdaq.com/articles/xbi-clvs-kite-tsro-large-inflows-detected-etf-2017-03-02", "https://www.nasdaq.com/articles/commit-purchase-clovis-oncology-35-earn-123-using-options-2017-02-23", "https://www.nasdaq.com/articles/tesaro-wins-fda-approval-for-ovarian-cancer-drug-zejula-2017-03-28", "https://www.nasdaq.com/articles/xbi-jpnl-big-etf-outflows-2017-02-22", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-sage-bax-clvs-2017-02-17", "https://www.nasdaq.com/articles/boxer-capital-llc-buys-avexis-beigene-alnylam-pharmaceuticals-sells-biomarin-2017-02-16", "https://www.nasdaq.com/articles/xbi-uge-big-etf-outflows-2017-02-14", "https://www.nasdaq.com/articles/3-scorching-hot-biotech-stocks-are-they-buys-2017-02-08", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-xbi-clvs-acad-uthr-2017-02-02", "https://www.nasdaq.com/articles/3-mid-cap-biotech-stocks-buy-february-2017-01-29", "https://www.nasdaq.com/articles/clovis-clvs-q4-loss-wider-than-expected-focus-on-rubraca-2017-02-23", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-dwas-2017-01-26", "https://www.nasdaq.com/articles/3-biotechs-likely-be-acquired-2017-2017-01-22", "https://www.nasdaq.com/articles/whats-behind-clovis-clvs-one-year-rally-of-146.3-2017-01-17", "https://www.nasdaq.com/articles/thursdays-etf-movers-xbi-kre-2017-01-12", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-clovis-oncology-pfizer-roches-sanofi-and-regeneron-2017", "https://www.nasdaq.com/articles/clovis-declares-pricing-of-upsized-offering-of-common-stock-2017-01-04", "https://www.nasdaq.com/articles/pre-market-most-active-jan-4-2017-bbva-smi-azn-nvo-lyg-tot-clvs-nvda-nvls-tvix-aapl-qqq", "https://www.nasdaq.com/articles/clovis-oncology-clvs-in-focus%3A-stock-moves-5.6-higher-2017-01-27", "https://www.nasdaq.com/articles/christmas-came-early-these-biotech-stocks-2016-12-21", "https://www.nasdaq.com/articles/4-stocks-watch-strong-technical-momentum-2016-12-21", "https://www.nasdaq.com/articles/clovis-scales-52-week-high-on-early-fda-nod-for-rubraca-2016-12-20", "https://www.nasdaq.com/articles/surprise-clovis-oncology-nabs-early-ok-2016-12-19", "https://www.nasdaq.com/articles/stock-market-roundup-dec-19-googl-bbry-self-driving-cars-clvs-soars-2016-12-19", "https://www.nasdaq.com/articles/heres-why-clovis-oncology-clvs-stock-soaring-today-2016-12-19", "https://www.nasdaq.com/articles/short-sellers-are-betting-big-against-clovis-oncology-heres-why-theyre-probably-right-2016", "https://www.nasdaq.com/articles/biotech-stocks-what-watch-2017-2016-12-29", "https://www.nasdaq.com/articles/heres-why-these-biopharma-stocks-soared-least-10-today-2016-11-09", "https://www.nasdaq.com/articles/clovis-oncology-reaches-analyst-target-price-2016-10-11", "https://www.nasdaq.com/articles/why-clovis-oncology-inc-rose-527-september-2016-10-10", "https://www.nasdaq.com/articles/tesaro-inc-flying-high-today-and-could-go-higher-here-2016-10-10", "https://www.nasdaq.com/articles/3-cancer-drugs-could-get-fda-ok-next-year-2016-10-09", "https://www.nasdaq.com/articles/notable-friday-option-activity-clvs-tsn-anf-2016-10-07", "https://www.nasdaq.com/articles/why-clovis-oncology-shares-are-falling-145-today-2016-10-07", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph%3A-what-awaits-in-q4-earnings-2016-12-01", "https://www.nasdaq.com/articles/5-top-performing-stocks-best-etf-q3-2016-09-30", "https://www.nasdaq.com/articles/health-care-sector-update-09282016-clvs-kpti-2016-09-28", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-clovis-oncology-clvs-2016-09-26", "https://www.nasdaq.com/articles/3-biotechs-could-be-ma-targets-2016-09-24", "https://www.nasdaq.com/articles/why-clovis-oncology-inc-clvs-philip-morris-international-inc.-pm-and-weyerhaeuser-co-wy", "https://www.nasdaq.com/articles/stocks-futures-buoyed-bank-japan-move-long-term-rates-waiting-fomc-2016-09-21", "https://www.nasdaq.com/articles/commit-buy-clovis-oncology-1750-earn-235-annualized-using-options-2016-09-20", "https://www.nasdaq.com/articles/6-best-performing-drug-stocks-september-2016-10-03", "https://www.nasdaq.com/articles/4-momentum-stocks-watch-2016-09-13", "https://www.nasdaq.com/articles/clovis-oncology-still-strong-buy-2016-09-12", "https://www.nasdaq.com/articles/clovis-rucaparib-not-to-face-fda-advisory-panel-stock-up-2016-09-09", "https://www.nasdaq.com/articles/clovis-oncology-clvs-in-focus%3A-stock-moves-15-higher-2016-09-09", "https://www.nasdaq.com/articles/why-clovis-oncology-inc-soaring-today-2016-09-08", "https://www.nasdaq.com/articles/clovis-oncology-speeds-toward-possible-launch-ovarian-cancer-red-flags-remain-2016-09-01", "https://www.nasdaq.com/articles/health-care-sector-update-08312016-veevclvspfe-2016-08-31", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-clovis-oncology-clvs-2016-09-15", "https://www.nasdaq.com/articles/4-momentum-stocks-watch-2016-09-13", "https://www.nasdaq.com/articles/5-companies-should-consider-kicking-their-ceos-curb-2016-08-25", "https://www.nasdaq.com/articles/news-good-or-bad-can-create-buying-opportunities-2016-08-24", "https://www.nasdaq.com/articles/pre-market-most-active-aug-24-2016-eric-nvo-azn-expr-clvs-lyg-bcs-ldos-qqq-osur-gpro-xiv", "https://www.nasdaq.com/articles/clovis-clvs-stock-fda-priority-review-rucaparib-2016-08-24", "https://www.nasdaq.com/articles/why-best-buy-co-inc-bby-clovis-oncology-inc-clvs-and-toll-brothers-inc-tol-are-3-of-todays", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-clvs-feye-lvs-2016-08-19", "https://www.nasdaq.com/articles/energy-sector-update-08312016-veevclvspfe-2016-08-31", "https://www.nasdaq.com/articles/notable-friday-option-activity-qvca-clvs-hos-2016-08-05", "https://www.nasdaq.com/articles/7-biotech-stocks-pivotal-catalysts-2017-2016-08-02", "https://www.nasdaq.com/articles/tuesdays-etf-movers-gdx-xbi-2016-08-02", "https://www.nasdaq.com/articles/math-shows-iyh-can-go-172-2016-08-01", "https://www.nasdaq.com/articles/3-shocking-biotech-flops-2016-so-far-2016-07-08", "https://www.nasdaq.com/articles/overnight-double-could-these-drugmakers-be-next-2016-07-01", "https://www.nasdaq.com/articles/clovis-oncology-clvs-jumps%3A-stock-adds-21.9-in-session-2016-06-30", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-clovis-oncology-clvs-2016-08-18", "https://www.nasdaq.com/articles/whats-causing-clovis-oncology-shares-skyrocket-today-2016-06-29", "https://www.nasdaq.com/articles/5-reasons-hate-biotech-stocks-2016-06-23", "https://www.nasdaq.com/articles/investors-win-when-boring-beats-sexy-xlu-2016-06-21", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-iyh-2016-04-19", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-intercept-clovis-abbvie-relypsa-and-horizon-pharma-2016", "https://www.nasdaq.com/articles/health-care-sector-update-04132016-aphb-rprx-clvs-2016-04-13", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-advisory-panels-say-yes-intercept-no-clovis-2016-04-13", "https://www.nasdaq.com/articles/why-tesaro-inc-tsro-clovis-oncology-inc-clvs-and-twilio-inc-twlo-are-3-of-todays-best", "https://www.nasdaq.com/articles/clovis-drops-fda-panel-seeks-more-data-on-rociletinib-2016-04-13", "https://www.nasdaq.com/articles/health-care-sector-update-04132016-pstirprxclvs-2016-04-13", "https://www.nasdaq.com/articles/health-care-sector-update-04122016-amgn-mrk-abt-pfe-jnj-clvs-cbrp-2016-04-12", "https://www.nasdaq.com/articles/why-horizon-pharma-och-ziff-capital-management-and-clovis-oncology-slumped-today-2016-04", "https://www.nasdaq.com/articles/clovis-oncologys-failure-big-win-astrazeneca-2016-04-12", "https://www.nasdaq.com/articles/health-care-sector-update-04122016-clvscrbpttoo-2016-04-12", "https://www.nasdaq.com/articles/clovis-hits-52-week-low-post-rociletinib-briefing-documents-2016-04-11", "https://www.nasdaq.com/articles/why-clovis-oncology-inc-clvs-seagate-technology-plc-stx-and-sprint-corp-s-are-3-of-todays", "https://www.nasdaq.com/articles/clovis-drops-fda-panel-seeks-more-data-on-rociletinib-2016-04-13", "https://www.nasdaq.com/articles/clovis-oncology-clvs-catches-eye%3A-stock-moves-6-higher-2016-04-07", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-clvs-tnet-cbm-2016-04-01", "https://www.nasdaq.com/articles/10-biotech-stocks-with-big-catalysts-coming-this-quarter-2016-03-31", "https://www.nasdaq.com/articles/sum-pieces-iyh-could-be-worth-170-2016-03-16", "https://www.nasdaq.com/articles/is-clovis-oncology-clvs-stock-a-solid-choice-right-now-2016-03-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-incyte-intercept-pharma-gilead-aegerion-and-clovis-2016", "https://www.nasdaq.com/articles/pre-market-most-active-apr-8-2016-tvix-nok-bac-tot-pbr-fcx-xiv-vrx-mrcy-cme-clvs-qqq-2016", "https://www.nasdaq.com/articles/3-upcoming-fda-decisions-were-most-excited-about-2016-02-13", "https://www.nasdaq.com/articles/implied-rxl-analyst-target-price-64-2016-02-10", "https://www.nasdaq.com/articles/clovis-clvs-begins-immunotherapy-combination-study-2016-01-28", "https://www.nasdaq.com/articles/commit-purchase-clovis-oncology-20-earn-20-using-options-2016-01-07", "https://www.nasdaq.com/articles/festivus-invest-us-its-time-airing-grievances-2015-12-23", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-ariad-clovis-oncology-regeneron-and-akebia", "https://www.nasdaq.com/articles/clovis-clvs-rociletinibs-review-period-extended-by-fda-2015-12-16", "https://www.nasdaq.com/articles/clovis-clvs-rociletinib-to-face-fda-advisory-panel-in-april-2016-02-15", "https://www.nasdaq.com/articles/why-shaken-confidence-caused-clovis-oncology-inc-crash-november-2015-12-10", "https://www.nasdaq.com/articles/top-3-drug-approvals-2015-2015-12-08", "https://www.nasdaq.com/articles/can-astrazeneca-live-its-45-billion-promise-2015-12-03", "https://www.nasdaq.com/articles/wednesdays-etf-movers-xbi-xop-2015-12-02", "https://www.nasdaq.com/articles/clovis-execution-risk-loss-credibility-regulatory-missteps-constrain-valuation-2015-11-27", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-clvs-aria-ajrd-2015-11-24", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-clovis-oncology-gilead-abbvie-and-medicines-company", "https://www.nasdaq.com/articles/are-these-3-small-cap-biotech-stocks-bargain-bin-buys-2015-12-13", "https://www.nasdaq.com/articles/company-news-for-november-17-2015-2015-11-17", "https://www.nasdaq.com/articles/pre-market-most-active-nov-17-2015-ge-syf-syf-pso-dks-xiv-urbn-fit-tvix-fb-clvs-qqq-2015", "https://www.nasdaq.com/articles/health-care-sector-update-11172015-clvs-azn-nvcr-2015-11-17", "https://www.nasdaq.com/articles/3-stocks-wall-street-hates-2015-11-17", "https://www.nasdaq.com/articles/why-clovis-oncology-inc-falling-again-2015-11-17", "https://www.nasdaq.com/articles/clovis-crashes-70-fda-seeks-more-data-on-rociletinib-2015-11-17", "https://www.nasdaq.com/articles/monday-sector-laggards-apparel-stores-drugs-2015-11-16", "https://www.nasdaq.com/articles/clovis-oncologys-loss-could-be-win-astrazeneca-2015-11-19", "https://www.nasdaq.com/articles/pre-market-most-active-nov-16-2015-ge-ibn-azn-cnhi-tvix-xiv-clvs-aapl-mar-sune-qqq-hot", "https://www.nasdaq.com/articles/why-clovis-oncology-dillards-and-urban-outfitters-slumped-today-2015-11-16", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-clvs-mhld-untd-2015-11-16", "https://www.nasdaq.com/articles/mondays-etf-movers-xop-xbi-2015-11-16", "https://www.nasdaq.com/articles/clovis-posts-wider-than-expected-loss-in-q3-shares-down-2015-11-09", "https://www.nasdaq.com/articles/use-options-chance-buy-clvs-45-discount-2015-11-02", "https://www.nasdaq.com/articles/interesting-clvs-put-and-call-options-december-18th-2015-10-21", "https://www.nasdaq.com/articles/heres-why-clovis-oncologys-stock-getting-pummeled-today-2015-11-16", "https://www.nasdaq.com/articles/why-biotech-stock-bucking-biotechs-bloodbath-2015-10-08", "https://www.nasdaq.com/articles/use-options-chance-buy-clvs-48-discount-2015-10-02", "https://www.nasdaq.com/articles/clovis-rociletinib-under-review-in-u.s.-eu-for-lung-cancer-2015-09-30", "https://www.nasdaq.com/articles/interesting-clvs-put-and-call-options-november-20th-2015-09-24", "https://www.nasdaq.com/articles/these-clinical-stage-biotechs-could-be-ripe-takeover-2015-09-13", "https://www.nasdaq.com/articles/clovis-oncology-clvs-jumps%3A-stock-adds-13.8-in-session-2015-09-10", "https://www.nasdaq.com/articles/why-clovis-oncology-inc-shares-are-rocketing-higher-today-2015-09-09", "https://www.nasdaq.com/articles/3-cancer-companies-watch-closely-2016-2015-10-20", "https://www.nasdaq.com/articles/clovis-oncology-breaks-below-200-day-moving-average-notable-clvs-2015-08-20", "https://www.nasdaq.com/articles/clovis-oncology-strikes-deal-with-roche-for-rociletinib-2015-08-12", "https://www.nasdaq.com/articles/first-week-september-18th-options-trading-clovis-oncology-clvs-2015-07-21", "https://www.nasdaq.com/articles/use-options-chance-buy-clvs-43-discount-2015-07-14", "https://www.nasdaq.com/articles/pre-market-most-active-jul-9-2015-gsk-nok-xiv-aapl-bac-baba-bp-aa-qqq-tvix-fb-clvs-2015-07", "https://www.nasdaq.com/articles/health-care-sector-update-07092015-clvsipciaqxp-2015-07-09", "https://www.nasdaq.com/articles/health-care-sector-update-07082015-clvsaemd-2015-07-08", "https://www.nasdaq.com/articles/first-week-clvs-april-2016-options-trading-2015-08-28", "https://www.nasdaq.com/articles/immunogen-surges-on-positive-ovarian-cancer-study-data-analyst-blog-2015-06-02", "https://www.nasdaq.com/articles/clovis-oncology-clvs-jumps%3A-stock-adds-16.7-in-session-tale-of-the-tape-2015-05-15", "https://www.nasdaq.com/articles/health-care-sector-update-05152015-clvstconrkda-2015-05-15", "https://www.nasdaq.com/articles/clovis-oncology-clvs-falls%3A-stock-goes-down-5.3-tale-of-the-tape-2015-04-20", "https://www.nasdaq.com/articles/why-clovis-oncology-inc-soaring-higher-today-2015-04-13", "https://www.nasdaq.com/articles/mondays-etf-movers-xbi-gdxj-2015-04-13", "https://www.nasdaq.com/articles/clovis-oncology-clvs-in-focus%3A-stock-moves-8-higher-tale-of-the-tape-2015-04-08", "https://www.nasdaq.com/articles/clovis-oncology-starts-rolling-nda-submission-for-rociletinib-analyst-blog-2015-07-02", "https://www.nasdaq.com/articles/clovis-oncologys-rucaparib-gets-breakthrough-status-analyst-blog-2015-04-07", "https://www.nasdaq.com/articles/why-clovis-oncology-shares-soared-higher-today-2015-04-07", "https://www.nasdaq.com/articles/health-care-sector-update-04072015-clvsbindocul-2015-04-07", "https://www.nasdaq.com/articles/commit-buy-clovis-oncology-65-earn-164-annualized-using-options-2015-03-06", "https://www.nasdaq.com/articles/clovis-oncology-inc.-clvs-in-focus%3A-stock-jumps-5.9-tale-of-the-tape-2015-01-14", "https://www.nasdaq.com/articles/astrazenecas-lynparza-approved-in-eu-for-ovarian-cancer-analyst-blog-2014-12-19", "https://www.nasdaq.com/articles/clovis-oncology-clvs-shares-cross-below-200-dma-2014-11-17", "https://www.nasdaq.com/articles/tuesdays-etf-movers-xbi-gdx-2015-04-07", "https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-buy-now-2014-10-23", "https://www.nasdaq.com/articles/big-news-these-5-stocks-esmo-2014-09-30", "https://www.nasdaq.com/articles/clvs-january-2016-options-begin-trading-2014-09-04", "https://www.nasdaq.com/articles/clovis-oncology-clvs-falls%3A-stock-goes-down-6.8-tale-of-the-tape-2014-09-04", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-mixed-pre-market-2014-09-04", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-04-1", "https://www.nasdaq.com/articles/interesting-clvs-put-and-call-options-august-16th-2014-06-25", "https://www.nasdaq.com/articles/astrazenecas-lynparza-a-step-closer-to-european-approval-analyst-blog-2014-10-27", "https://www.nasdaq.com/articles/3-beaten-down-biotech-stocks-buy-now-2014-10-23", "https://www.nasdaq.com/articles/clovis-oncology-clvs-jumps%3A-stock-rises-6.2-tale-of-the-tape-2014-06-06", "https://www.nasdaq.com/articles/sector-update-technology-shares-flat-pre-market-clovis-oncology-upgraded-buy-stifel", "https://www.nasdaq.com/articles/sector-update-healthcare-healthcare-2014-06-05", "https://www.nasdaq.com/articles/monday-sector-laggards-drugs-manufacturing-stocks-2014-06-02", "https://www.nasdaq.com/articles/clovis-oncology-clvs-falls%3A-stock-goes-down-9.2-tale-of-the-tape-2014-05-28", "https://www.nasdaq.com/articles/clovis-oncology-initiates-study-on-co-1686-analyst-blog-2014-06-24", "https://www.nasdaq.com/articles/healthcare-stocks-sputtering-clovis-oncology-gaining-after-cancer-treatment-wins", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-05-20-0", "https://www.nasdaq.com/articles/clovis-oncology-inc.-clvs-in-focus%3A-stock-surges-16-tale-of-the-tape-2014-05-16", "https://www.nasdaq.com/articles/fridays-etf-movers-vwo-xbi-2014-05-16", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-05-15-0", "https://www.nasdaq.com/articles/healthcare-stocks-sliding-clovis-rallies-after-posting-early-indications-cancer-drug", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-baxter-12-plans-split-2-companies-2014-03", "https://www.nasdaq.com/articles/clovis-gets-breakthrough-therapy-designation-analyst-blog-2014-05-22", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-clovis-oncology-inc-clvs-tale-of-the-tape-2014-01-10", "https://www.nasdaq.com/articles/2013-review-good-and-bad-2013-12-27", "https://www.nasdaq.com/articles/pre-market-most-active-dec-4-2013-jcp-expr-nok-bac-nclh-qqq-alu-san-ccxi-tsla-omed-clvs", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-12-04-0", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-clovis-sinks-2-pricing-public-offering", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-drew-industries-net-income-rises-year-over", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-11-01-1", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-03-27-0", "https://www.nasdaq.com/articles/3-top-ranked-biotech-mutual-funds-surging-higher-best-of-funds-2013-09-26", "https://www.nasdaq.com/articles/us-futures-nearly-unchanged-market-mulls-washington-budget-debt-limit-risks-2013-09-25", "https://www.nasdaq.com/articles/us-futures-slightly-lower-risk-government-shutdown-looms-2013-09-25", "https://www.nasdaq.com/articles/clovis-oncology-clvs-surges%3A-stock-gains-7.3-in-session-analyst-blog-2013-09-18", "https://www.nasdaq.com/articles/clovis-co-1686-value-derived-data-supports-valuation-2013-06-12", "https://www.nasdaq.com/articles/pre-market-most-active-jun-12-2013-ctb-nct-wday-bac-vod-s-nok-gt-grfs-arna-siri-clvs-2013", "https://www.nasdaq.com/articles/clovis-oncology-clvs-love-story-2013-03-14", "https://www.nasdaq.com/articles/clovis-sinks-on-lack-of-buyer-interest-analyst-blog-2013-09-26", "https://www.nasdaq.com/articles/pre-market-most-active-nov-12-2012-tie-un-bac-gild-mt-clvs-fb-jef-grpn-dcm-nktr-qqq-2012", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-near-flat-jc-penney-falling-further-2012-11-12", "https://www.nasdaq.com/articles/investing-biotech-stocks-journey-profits-requires-good-gps-2012-08-31", "https://www.nasdaq.com/articles/mid-day-market-update-markets-slow-their-rally-jc-penney-spikes-lower-2012-11-12"], "Content": []}